Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $2.98 billion. The enterprise value is $2.08 billion.
| Market Cap | 2.98B |
| Enterprise Value | 2.08B |
Important Dates
The next confirmed earnings date is Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNLI has 159.85 million shares outstanding. The number of shares has increased by 5.80% in one year.
| Current Share Class | 159.85M |
| Shares Outstanding | 159.85M |
| Shares Change (YoY) | +5.80% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 2.97% |
| Owned by Institutions (%) | 99.85% |
| Float | 155.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 827.62 |
| Forward PS | 30.94 |
| PB Ratio | 3.57 |
| P/TBV Ratio | 3.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 577.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.37, with a Debt / Equity ratio of 0.05.
| Current Ratio | 8.37 |
| Quick Ratio | 7.95 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.93% and return on invested capital (ROIC) is -769.52%.
| Return on Equity (ROE) | -54.93% |
| Return on Assets (ROA) | -29.15% |
| Return on Invested Capital (ROIC) | -769.52% |
| Return on Capital Employed (ROCE) | -50.75% |
| Weighted Average Cost of Capital (WACC) | 9.76% |
| Revenue Per Employee | $7,108 |
| Profits Per Employee | -$1.01M |
| Employee Count | 507 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $102,000 in taxes.
| Income Tax | 102,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.02% in the last 52 weeks. The beta is 1.02, so DNLI's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | +10.02% |
| 50-Day Moving Average | 21.34 |
| 200-Day Moving Average | 21.19 |
| Relative Strength Index (RSI) | 41.62 |
| Average Volume (20 Days) | 1,897,488 |
Short Selling Information
The latest short interest is 15.46 million, so 9.67% of the outstanding shares have been sold short.
| Short Interest | 15.46M |
| Short Previous Month | 17.14M |
| Short % of Shares Out | 9.67% |
| Short % of Float | 9.97% |
| Short Ratio (days to cover) | 8.91 |
Income Statement
In the last 12 months, DNLI had revenue of $3.60 million and -$511.45 million in losses. Loss per share was -$2.83.
| Revenue | 3.60M |
| Gross Profit | -397.21M |
| Operating Income | -541.95M |
| Pretax Income | -511.35M |
| Net Income | -511.45M |
| EBITDA | -526.06M |
| EBIT | -541.95M |
| Loss Per Share | -$2.83 |
Balance Sheet
The company has $710.47 million in cash and $37.69 million in debt, with a net cash position of $902.32 million or $5.64 per share.
| Cash & Cash Equivalents | 710.47M |
| Total Debt | 37.69M |
| Net Cash | 902.32M |
| Net Cash Per Share | $5.64 |
| Equity (Book Value) | 835.18M |
| Book Value Per Share | 5.23 |
| Working Capital | 663.84M |
Cash Flow
In the last 12 months, operating cash flow was -$434.04 million and capital expenditures -$3.42 million, giving a free cash flow of -$437.46 million.
| Operating Cash Flow | -434.04M |
| Capital Expenditures | -3.42M |
| Depreciation & Amortization | 15.89M |
| Net Borrowing | -1.42M |
| Free Cash Flow | -437.46M |
| FCF Per Share | -$2.74 |
Margins
| Gross Margin | n/a |
| Operating Margin | -15,037.38% |
| Pretax Margin | -14,188.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.80% |
| Shareholder Yield | n/a |
| Earnings Yield | -15.19% |
| FCF Yield | -14.67% |
Analyst Forecast
The average price target for DNLI is $35.75, which is 91.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.75 |
| Price Target Difference | 91.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNLI has an Altman Z-Score of 1.45 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.45 |
| Piotroski F-Score | 1 |